Breaking: Pfizer's Covid-19 antiviral reduces hospitalizations by 89%, could prove a formidable foe for Merck's pill
Pfizer on Friday unveiled statistically significant efficacy data for its potential Covid-19 pill among people who haven’t been hospitalized with the virus. The data will likely lead to a quick EUA from the FDA and add to a growing field of effective, easy-to-use treatments.
Data from a scheduled interim analysis showed an 89% reduction in risk of Covid-related hospitalization or death from any cause compared to placebo in patients treated within three days of symptom onset. Pfizer said it halted enrollment in the trial because of the positive results, and in consultation with the FDA.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.